ASCO - Poster: Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer

CHICAGO, IL USA (UroToday.com) - Presented by Jong Chul Park, A. Oliver Sartor, Rana Sullivan, Serina King, and Emmanuel S. Antonarakis at the American Society of Clinical Oncology (ASCO) Annual Meeting - Illumination & Innovation: Transforming Data into Learning - May 29 - June 2, 2015 - Chicago, Illinois USA

ASCO - Poster: Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients

CHICAGO, IL USA (UroToday.com) - Presented by Fred Saad, Joan Carles, Silke Gillessen, Daniel Heinrich, Jeremy Gratt, Kurt Miller, Sten Nilsson, Joe O'Sullivan, Marcello Tucci, Manfred Wirth, and Axel Heidenreich at the American Society of Clinical Oncology (ASCO) Annual Meeting - Illumination & Innovation: Transforming Data into Learning - May 29 - June 2, 2015 - Chicago, Illinois USA

ASCO - Radium-223 provides pain relief for patients with CRPC and bone metastases - Session Highlights

CHICAGO, IL USA (UroToday.com) - Radium-223 dichloride (Ra-223), a first-in-class alpha-emitting radiopharmaceutical, was associated with meaningful pain relief for patients with castrate-resistant prostate cancer (CRPC) and symptomatic bone metastases.

ASCO - Timing of radium-223 in today’s treatment landscape - Session Highlights

CHICAGO, IL USA (UroToday.com) - Dr. Tanya Dorff, assistant professor of medicine at the University of Southern California, gave an update on data directing timing of radium-223 in the treatment of men with prostate cancer that has metastasized to bone.

ASCO - Radium-223 linked to longer overall survival in international study of mCRPC patients with bone metastases - Session Highlights

CHICAGO, IL USA (UroToday.com) - Radium-223 was generally well tolerated and no new safety concerns emerged from a recently reported phase 3b international, prospective, interventional, open-label, multicenter early access program (EAP) of metastatic castrate-resistant prostate cancer (mCRPC) patients from Europe, Canada, and Israel.

ASCO - Radium-223 early access program (EAP) enlightens safety, tolerability profile in a U.S. population of CRPC patients - Session Highlights

CHICAGO, IL USA (UroToday.com) - Radium-223, the first-approved alpha-emitting radiopharmaceutical, was safe and well-tolerated among patients with castrate-resistant prostate cancer (CRPC), regardless of prior abiraterone and/or enzalutamide use, in findings from a United States-based early access program (EAP).